Cargando…

Evaluation of ABO/Rh blood group distributions in papillary thyroid cancer patients

The study aimed to evaluate the ABO/Rh blood group distributions and their relationship with clinical-pathological features in papillary thyroid cancer patients. It was planned as a retrospective case-controlled study. The blood group distributions of the patients were contrasted with that of the ge...

Descripción completa

Detalles Bibliográficos
Autor principal: Dogan, Ozlem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419498/
https://www.ncbi.nlm.nih.gov/pubmed/37565904
http://dx.doi.org/10.1097/MD.0000000000034564
_version_ 1785088535768858624
author Dogan, Ozlem
author_facet Dogan, Ozlem
author_sort Dogan, Ozlem
collection PubMed
description The study aimed to evaluate the ABO/Rh blood group distributions and their relationship with clinical-pathological features in papillary thyroid cancer patients. It was planned as a retrospective case-controlled study. The blood group distributions of the patients were contrasted with that of the general population. Additionally, the association between clinical-pathological variables and blood group distribution was assessed. Two hundred and ninety-three patients were involved in the study. The median age was 48 years, and the majority of patients were female (84.3%). The most common variants of papillary thyroid cancer were follicular, classical, and oncocytic. The majority of the patients had stage 1 (91.1%) disease at the time of diagnosis. ABO blood group distributions in the patient (47.4% A, 11.9% B, 8.2% AB, 32.4% O) and control (42% A, 16% B, 8% AB, 34% O) groups were found to be similar (P = .8). In terms of Rh factor, there was a comparable distribution for the characteristics of the patient and healthy control group (P = .6). There was no association between clinical and pathological variables and blood group distributions (gender, age, tumor stage, tumor location, and pathological tumor variant). Comparing patients with papillary thyroid carcinoma to the healthy control group, the prevalence of the A blood group numerically increased while the prevalence of the B blood group numerically decreased, but it was not statistically significant. In addition, ABO/Rh blood type and clinical and pathological variables did not relate.
format Online
Article
Text
id pubmed-10419498
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104194982023-08-12 Evaluation of ABO/Rh blood group distributions in papillary thyroid cancer patients Dogan, Ozlem Medicine (Baltimore) 5700 The study aimed to evaluate the ABO/Rh blood group distributions and their relationship with clinical-pathological features in papillary thyroid cancer patients. It was planned as a retrospective case-controlled study. The blood group distributions of the patients were contrasted with that of the general population. Additionally, the association between clinical-pathological variables and blood group distribution was assessed. Two hundred and ninety-three patients were involved in the study. The median age was 48 years, and the majority of patients were female (84.3%). The most common variants of papillary thyroid cancer were follicular, classical, and oncocytic. The majority of the patients had stage 1 (91.1%) disease at the time of diagnosis. ABO blood group distributions in the patient (47.4% A, 11.9% B, 8.2% AB, 32.4% O) and control (42% A, 16% B, 8% AB, 34% O) groups were found to be similar (P = .8). In terms of Rh factor, there was a comparable distribution for the characteristics of the patient and healthy control group (P = .6). There was no association between clinical and pathological variables and blood group distributions (gender, age, tumor stage, tumor location, and pathological tumor variant). Comparing patients with papillary thyroid carcinoma to the healthy control group, the prevalence of the A blood group numerically increased while the prevalence of the B blood group numerically decreased, but it was not statistically significant. In addition, ABO/Rh blood type and clinical and pathological variables did not relate. Lippincott Williams & Wilkins 2023-08-11 /pmc/articles/PMC10419498/ /pubmed/37565904 http://dx.doi.org/10.1097/MD.0000000000034564 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 5700
Dogan, Ozlem
Evaluation of ABO/Rh blood group distributions in papillary thyroid cancer patients
title Evaluation of ABO/Rh blood group distributions in papillary thyroid cancer patients
title_full Evaluation of ABO/Rh blood group distributions in papillary thyroid cancer patients
title_fullStr Evaluation of ABO/Rh blood group distributions in papillary thyroid cancer patients
title_full_unstemmed Evaluation of ABO/Rh blood group distributions in papillary thyroid cancer patients
title_short Evaluation of ABO/Rh blood group distributions in papillary thyroid cancer patients
title_sort evaluation of abo/rh blood group distributions in papillary thyroid cancer patients
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419498/
https://www.ncbi.nlm.nih.gov/pubmed/37565904
http://dx.doi.org/10.1097/MD.0000000000034564
work_keys_str_mv AT doganozlem evaluationofaborhbloodgroupdistributionsinpapillarythyroidcancerpatients